FeesSafety
Pluang+

Bitget offers tokenized subscription for Anthropic's U.S. IPO with VIP and public rounds and fees.

Market News
03 Nov 2026, 13:58 WIB
Tokenpost
View Source
Neutral
Bitget offers tokenized subscription for Anthropic's U.S. IPO with VIP and public rounds and fees.

Bitget is launching a tokenized subscription service for Anthropic's upcoming U.S. IPO, allowing users to subscribe using Tether (USDT) or USDGO. The service offers two rounds: a VIP round with a 12% fee and a public round with a 5% fee, but allocations do not grant direct share ownership or shareholder rights. VIP users can commit between $100 and $3 million from Nov. 5 to Nov. 9, while the public round allows commitments from $100 to $25,000 starting Nov. 10 until the day before the IPO. Allocations will be delivered as Anthropic rTokens (rANT), which are backed by Anthropic stock but are not official shares. This product is separate from Bitget's other IPO-related offerings and aims to provide a new way for investors to engage with the IPO.

The story about Bitget's tokenized Anthropic IPO subscription service is presented here with market context from Pluang's cryptocurrency sector. For readers following major cryptocurrencies, 12 out of 50 rose while 37 fell today. Notable movers include EOS at Rp12.649 with an 8.13% increase, CRV at Rp4.721 with a 5.07% decrease, and BAT at Rp2.296 with a 4.09% decrease. This data is as of Nov 03, 2026 19:03 WIB.

More News

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...

Company Fundamentals
Bullish
19 minutes ago
Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...

Market News
Bullish
19 minutes ago
Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...

Market News
Bullish
19 minutes ago
Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...

Company Fundamentals
Neutral
1 hour ago
Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...

Company Fundamentals
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App